FDA Reauthorization Act of 2017

The FDA Reauthorization Act of 2017, also known as Bill 115 hr 2430, is a piece of legislation that aims to reauthorize the Food and Drug Administration (FDA) to continue its important work in regulating and overseeing the safety and efficacy of food, drugs, medical devices, and other products.

The bill includes provisions to reauthorize the FDA's user fee programs, which help fund the agency's review of new drugs and medical devices. These user fees are paid by pharmaceutical and medical device companies in exchange for the FDA's review and approval of their products.

Additionally, the FDA Reauthorization Act of 2017 includes measures to improve the FDA's regulatory processes, enhance the agency's ability to respond to public health emergencies, and increase transparency and accountability within the FDA. Overall, the bill aims to ensure that the FDA has the resources and authority necessary to protect public health and safety, while also promoting innovation and access to new medical treatments and technologies.